Singapore is entering its fourth phase of bioscience sector development. Though Singapore has succeeded in building a reputation as a regional biomed cluster, challenges remain.
In this white paper, we review the development to date and in comparison with a few other bioscience clusters: Israel, Taiwan and South Korea. We then highlight R&D, commercialisation and talent development opportunities that can help Singapore sustain and entrench its position over the next ten years as a biopolis of Asia.
Download the whitepaper to understand:
- How does Singapore compare to bioscience clusters in Israel, Taiwan, South Korea?
- Three strategic focus areas to maximise relevance and return on investment in Singapore’s bioscience sector
- Two ways to speed up the commercialisation of clinical ideas